Drug intelligence / Profile preview

B-CD13

Development stage: Preclinical
Lead developer: University of Arizona
Modality: Peptides

Overview

B-CD13 is an experimental peptide designed to block CD13 (also known as Aminopeptidase N) signaling. Research presented at the AHA 2023 meeting suggests that CD13 activation mediates a phenotypic switch from pericytes to proliferative smooth muscle cell-like cells in pulmonary hypertension (PH). In animal models (NFU1 rats), treatment with B-CD13 attenuated right ventricular systolic pressure, reduced vascular remodeling, and improved pericyte-endothelial cell interactions. It also reduced the high proliferation rates of isolated pulmonary artery smooth muscle cells (PASMC) from PH patients.

Targets

ANPEP (Aminopeptidase N)

Beyond the preview

Go deeper on B-CD13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-CD13.

Explore the full profile